CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin

Molecular Cancer Therapeutics

Volumn 14, Issue 6, 2015, Pages 1376-1384

  Chen, Robert ^a   Hou, Jessie ^a   Newman, Edward ^a   Kim, Young ^a   Donohue, Cecile ^a   Liu, Xueli ^b   Thomas, Sandra H ^a   Forman, Stephen J ^a   Kane, Susan E ^a  

^a Department of Hematology and Hematopoietic Cell Transplantation ^*  (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 1; VEDOTIN; ANTIBODY CONJUGATE; MULTIDRUG RESISTANCE PROTEIN; OLIGOPEPTIDE;

ARTICLE; CANCER PATIENT; CANCER THERAPY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DISEASE COURSE; DOWN REGULATION; DRUG ACCUMULATION; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LARGE CELL LYMPHOMA; MTS ASSAY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; UPREGULATION; WESTERN BLOTTING; ANAPLASTIC LARGE CELL LYMPHOMA; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; IC50; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD30; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; LYMPHOMA, LARGE-CELL, ANAPLASTIC; OLIGOPEPTIDES; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 84942114899     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0036     Document Type: Article

References (21)

1. American Cancer Society. Cancer facts and figures 2014. Atlanta, Georgia: American Cancer Society; 2014. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/index.
2. Quddus F, Armitage JO. Salvage therapy for Hodgkin's lymphoma. Cancer J 2009;15:161-3.
3. Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK+ anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504.
4. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001;97:616-23.
5. Kuruvilla J, Nagy T, Pintilie M, Tsang R, Keating A, Crump M. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer 2006;106:353-60.
6. Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Piccaluga PP, et al. Hodgkin's lymphoma: the pathologist's viewpoint. J Clin Pathol 2002;55:162-76.
7. Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65.
8. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;30:2183-9.
9. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-6.
10. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, et al. U. S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845-9.
11. Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, et al. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem 2011;22:1994-2004.
12. Nathwani N, Krishnan AY, Huang Q, Kim Y, Karanes C, Smith EP, et al. Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma 2012;53:2051-3.
13. Shaffer DR, Savoldo B, Yi Z, Chow KK, Kakarla S, Spencer DM, et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011;117:4304-14.
14. O'Malley DP, Chizhevsky V, Grimm KE, Hii A, Weiss LM. Utility of BCL2, PD1, and CD25 immunohistochemical expression in the diagnosis of T-cell lymphomas. Appl Immunohistochem Mol Morphol 2014;22:99-104.
15. Berkowitz JL, Janik JE, Stewart DM, Jaffe ES, Stetler-Stevenson M, Shih JH, et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin Immunol 2014;155:176-87.
16. Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 2014;32:1246-57.
17. ClinicalTrials.gov [homepage on the Internet]. NCT02216890: safety study of SGN-CD70A in Cancer Patients 2014. Bothell, WA: Seattle Genetics Inc. [cited 2015 Apr. 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02216890.
18. O'Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008;68:5380-9.
19. Greaves W, Xiao L, Sanchez-Espiridion B, Kunkalla K, Dave KS, Liang CS, et al. Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol 2012;5:47.
20. Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275, 183. Invest New Drugs 2014;32:1083-95.
21. Du Y, Su T, Zhao L, Tan X, Chang W, Zhang H, et al. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer. PLoS One 2014;9:e99843.